SVB Leerink

Selected news for the capital firm - SVB Leerink, collected since 4/2019. Recent stories appear in Mayfield Recorder. This capital firm shares healthcare news with Pfizer, Merck, Gilead, AstraZeneca, Biotech and over a hundred others.

Please provide a valid email address.

Selected Headines

Date Headline (link) Source Relevant Snippet
2/23/2021 NeoGenomics (NASDAQ:NEO) Shares Down 5.4% Mayfield Recorder ... reports on NEO shares. Raymond James boosted their price objective on shares of NeoGenomics from $40.00 to $48.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 28th. SVB Leerink upped their price target on NeoGenomics from $50.00 to $60.00 and gave the stock an “outperform” rating in a research report on Friday, January 8th. Needham & Company LLC increased their price objective on ...
2/23/2021 Teladoc Health (NYSE:TDOC) Trading Down 8.1% Mayfield Recorder ... traded during trading, a decline of 8% from the average session volume of 3,090,471 shares. The stock had previously closed at $292.51.A number of equities analysts have recently weighed in on the company. SVB Leerink increased their target price on Teladoc Health from $246.00 to $256.00 and gave the stock an “outperform” rating in a research note on Thursday, October 29th. KeyCorp increased their target price on Teladoc ...
2/23/2021 Five Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference financialbuzz.com Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer are scheduled to participate in a fireside chat at the virtual SVB Leerink 10 th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 10:00 a.m. ET / 7:00 a.m. PT.Live audio webcast of the presentation will be accessible and available for ...
2/22/2021 Invitae Co. (NYSE:NVTA) to Post Q1 2021 Earnings of ($0.56) Per Share, SVB Leerink Forecasts dispatchtribunal.com US Crude Prices Plummet 4% as Russia and OPEC Consider Easing CapsInvitae Co. (NYSE:NVTA) – Research analysts at SVB Leerink reduced their Q1 2021 earnings per share estimates for shares of Invitae in a report issued on Wednesday, February 17th. SVB Leerink analyst P. Souda now forecasts that the medical research company will earn ($0.56) per share for the quarter, down from their prior forecast of ($0.47). SVB ...
2/22/2021 SVB Leerink Brokers Reduce Earnings Estimates for Veracyte, Inc. (NASDAQ:VCYT) The Markets Daily SVB Leerink Brokers Reduce Earnings Estimates for Veracyte, Inc. (NASDAQ:VCYT) Posted by Mitch Edgeman on Feb 22nd, 2021 // Comments offVeracyte, Inc. (NASDAQ:VCYT) – Analysts at SVB Leerink cut their Q1 2021 earnings per share estimates for shares of Veracyte in a research note issued on Wednesday, February 17th. SVB Leerink analyst P. Souda now anticipates that the biotechnology company will post earnings of ($0.04) per share for ...
2/22/2021 Raymond James Reiterates “Hold” Rating for GW Pharmaceuticals (NASDAQ:GWPH) zolmax.com ... NASDAQ:GWPH) ‘s stock had its “hold” rating reaffirmed by equities research analysts at Raymond James in a research report issued on Monday, AnalystRatings.com reports.Several other brokerages also recently commented on GWPH. SVB Leerink downgraded shares of GW Pharmaceuticals from an “outperform” rating to a “market perform” rating and raised their price objective for the stock from $200.00 to $220.00 in a research report on Thursday ...
2/22/2021 eHealth (NASDAQ:EHTH) Downgraded by Deutsche Bank Aktiengesellschaft dispatchtribunal.com ... rating for the company in a research report on Monday, February 1st. Truist dropped their price target on shares of eHealth from $200.00 to $100.00 in a research report on Monday, February 1st. Finally, SVB Leerink dropped their price target on shares of eHealth from $110.00 to $105.00 and set an outperform rating for the company in a research report on Monday, December 14th. One research analyst has rated the ...
2/22/2021 Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences Business Wire ... in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Company will participate in the following virtual investor conferences.10 th Annual SVB Leerink Global Healthcare Conference Date: Friday, February 26, 2021 Time: 2:20 p.m. Eastern Time Presenter: Richard J. Rubino, Chief Financial Officer Presentation Type: Fireside 41 st Annual Cowen Healthcare Conference Date: Tuesday, March 2, 2021 ...
2/22/2021 Karyopharm Therapeutics (NASDAQ:KPTI) Downgraded by Zacks Investment Research to Sell Daily Political ... several other reports. Morgan Stanley decreased their price target on shares of Karyopharm Therapeutics from $34.00 to $32.00 and set an overweight rating on the stock in a research note on Tuesday, November 3rd. SVB Leerink decreased their price target on shares of Karyopharm Therapeutics from $25.00 to $22.00 and set an outperform rating on the stock in a research note on Thursday, February 11th. Finally, Barclays decreased their price ...
2/22/2021 Oak Street Health, Inc. (NYSE:OSH) Given Average Rating of “Buy” by Brokerages Daily Political ... last year is $66.33. Several equities research analysts have weighed in on the company. Truist upped their price target on Oak Street Health from $60.00 to $72.00 in a report on Friday, December 18th. SVB Leerink upped their price target on Oak Street Health from $55.00 to $78.00 and gave the stock an “outperform” rating in a report on Wednesday, November 11th. Piper Sandler upped their price objective on ...
2/22/2021 Doctors 'highly positive' on AbbVie's Rinvoq in IBD, but not so much on Bristol Myers' Zeposia: analyst FiercePharma ... the highest across all the attributes listed—including clinical response, mucosal healing and safety. Bristol Myers Squibb’s recently approved multiple sclerosis drug Zeposia ranked as the least attractive.That’s the message an SVB Leerink team received from a February survey of 50 U.S. gastroenterologists and internal medicine physicians who combined treat over 10,000 IBD patients.Physicians intend to use more oral IBD meds in the next two to ...
2/22/2021 Equities Analysts Issue Forecasts for Globus Medical, Inc.'s Q1 2021 Earnings (NYSE:GMED) dispatchtribunal.com US Crude Prices Plummet 4% as Russia and OPEC Consider Easing CapsGlobus Medical, Inc. (NYSE:GMED) – Equities research analysts at SVB Leerink cut their Q1 2021 earnings per share estimates for shares of Globus Medical in a report released on Thursday, February 18th. SVB Leerink analyst R. Newitter now anticipates that the medical device company will earn $0.35 per share for the quarter, down from their prior forecast ...
2/22/2021 Q1 2021 EPS Estimates for Globus Medical, Inc. Reduced by SVB Leerink (NYSE:GMED) theenterpriseleader.com Q1 2021 EPS Estimates for Globus Medical, Inc. Reduced by SVB Leerink (NYSE:GMED) Posted by Joseph McCarthy on Feb 22nd, 2021Globus Medical, Inc. (NYSE:GMED) – SVB Leerink lowered their Q1 2021 EPS estimates for Globus Medical in a note issued to investors on Thursday, February 18th. SVB Leerink analyst R. Newitter now anticipates that the medical device company will post earnings per share of $0.35 for the ...
2/22/2021 Invitae (NYSE:NVTA) Raised to Buy at LADENBURG THALM/SH SH slatersentinel.com ... number of other research reports. Oppenheimer cut Invitae from an outperform rating to a market perform rating in a research note on Monday, February 1st. They noted that the move was a valuation call. SVB Leerink raised their price objective on shares of Invitae from $48.00 to $64.00 and gave the company an outperform rating in a research note on Wednesday, January 20th. Morgan Stanley upped their target price on ...
2/22/2021 FY2021 EPS Estimates for Blueprint Medicines Co. (NASDAQ:BPMC) Decreased by SVB Leerink rivertonroll.com FY2021 EPS Estimates for Blueprint Medicines Co. (NASDAQ:BPMC) Decreased by SVB Leerink Posted by Maria Luz-Campos on Feb 22nd, 2021 TweetBlueprint Medicines Co. (NASDAQ:BPMC) – SVB Leerink cut their FY2021 earnings estimates for shares of Blueprint Medicines in a research report issued on Thursday, February 18th. SVB Leerink analyst A. Berens now expects that the biotechnology company will earn ($6.42) per share for the year, down ...
2/22/2021 Invitae (NYSE:NVTA) Price Target Raised to $65.00 at SVB Leerink Daily Political Lumentum (NASDAQ:LITE) Earns Buy Rating from Susquehanna Invitae (NYSE:NVTA) Price Target Raised to $65.00 at SVB Leerink February 22nd, 2021 - Comments Off on Invitae (NYSE:NVTA) Price Target Raised to $65.00 at SVB Leerink - Filed Under - by Jeff Wilder TweetInvitae (NYSE:NVTA) had its price objective hoisted by SVB Leerink from $64.00 to $65.00 in a research note released on Thursday morning, Stock Target Advisor reports. SVB ...
2/22/2021 FY2021 EPS Estimates for Blueprint Medicines Co. (NASDAQ:BPMC) Decreased by SVB Leerink American Banking News Blueprint Medicines Co. (NASDAQ:BPMC) – SVB Leerink cut their FY2021 earnings estimates for shares of Blueprint Medicines in a research report issued on Thursday, February 18th. SVB Leerink analyst A. Berens now expects that the biotechnology company will earn ($6.42) per share for the year, down from their prior forecast of ($4.83). SVB Leerink has a “Outperform” rating and a $127.00 price target on the stock. SVB Leerink ...
2/22/2021 Sientra (NASDAQ:SIEN) Cut to Hold at Zacks Investment Research Ticker Report ... reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “Get Sientra alerts: Several other brokerages also recently issued reports on SIEN. SVB Leerink raised their price objective on shares of Sientra from $6.00 to $8.00 and gave the stock an outperform rating in a research note on Tuesday, November 10th. William Blair reaffirmed an outperform rating on ...
2/22/2021 NuVasive, Inc. (NASDAQ:NUVA) Expected to Post Quarterly Sales of $300.51 Million rivertonroll.com ... billion to $1.24 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow NuVasive. Get NuVasive alerts:Several equities analysts have issued reports on NUVA shares. SVB Leerink cut their price target on shares of NuVasive from $70.00 to $65.00 and set an “outperform” rating on the stock in a report on Friday, October 30th. Zacks Investment Research raised shares of ...
2/22/2021 Five Prime Therapeutics, Inc. ( NASDAQ: FPRX ) tod wapakdailynews.com Five Prime Therapeutics, Inc. ( NASDAQ: FPRX ) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer are scheduled to participate in a fireside chat at the virtual SVB Leerink 10 th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 10:00 a.m. ET / 7:00 a.m. PT.Live audio webcast of the presentation will be accessible and available for ...